Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

NCT00201799 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Graft-Versus-Host Disease

Interventions

DRUG: Infliximab

Sponsor

Ohio State University Comprehensive Cancer Center